Cargando…
Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
BACKGROUND/AIMS: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL). METHODS: A cross-sectional study analyzed FL patients who were t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960034/ https://www.ncbi.nlm.nih.gov/pubmed/30935195 http://dx.doi.org/10.3904/kjim.2018.196 |
_version_ | 1783487701936242688 |
---|---|
author | Kim, Hee Kyung Kang, Wonseok Sinn, Dong Hyun Lee, Joon Hyeok Kim, Won Seog Kim, Seok Jin |
author_facet | Kim, Hee Kyung Kang, Wonseok Sinn, Dong Hyun Lee, Joon Hyeok Kim, Won Seog Kim, Seok Jin |
author_sort | Kim, Hee Kyung |
collection | PubMed |
description | BACKGROUND/AIMS: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL). METHODS: A cross-sectional study analyzed FL patients who were treated with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab maintenance. RESULTS: Of 139 patients, 85 patients received R-CVP and 54 received R-CHOP. The characteristics did not differ significantly between the groups. Only grade 3 of FL was more common in R-CHOP. The complete response rate did not differ significantly between R-CHOP (50/54, 92.6%) and R-CVP (77/85, 90.6%). The number of disease relapses during rituximab maintenance did not differ significantly between the groups (p = 0.798). Therefore, the comparison of progression-free survival (PFS) showed no significant difference: the 3-year PFS rates for R-CVP and R-CHOP were 77% and 85%, respectively (p = 0.567). Although five of 56 hepatitis B virus (HBV) core antibody (anti-HBc)-positive patients experienced HBV reactivation, all cases of HBV reactivation were identified during regular monitoring for HBV DNA in blood, and were successfully managed with antiviral treatment. CONCLUSIONS: The survival outcomes of FL patients on rituximab maintenance after responding to R-CVP or R-CHOP were similar. Rituximab-containing immunochemotherapy followed by rituximab maintenance can be safely used for anti-HBc-positive patients if HBV DNA titer in blood can be regularly monitored. |
format | Online Article Text |
id | pubmed-6960034 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Korean Association of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-69600342020-01-22 Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance Kim, Hee Kyung Kang, Wonseok Sinn, Dong Hyun Lee, Joon Hyeok Kim, Won Seog Kim, Seok Jin Korean J Intern Med Original Article BACKGROUND/AIMS: Real-world data about the treatment outcomes of patients receiving rituximab-containing immunochemotherapy followed by rituximab maintenance are required to understand better the treatment for follicular lymphoma (FL). METHODS: A cross-sectional study analyzed FL patients who were treated with R-CVP (rituximab, cyclophosphamide, vincristine, and prednisone) or R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and rituximab maintenance. RESULTS: Of 139 patients, 85 patients received R-CVP and 54 received R-CHOP. The characteristics did not differ significantly between the groups. Only grade 3 of FL was more common in R-CHOP. The complete response rate did not differ significantly between R-CHOP (50/54, 92.6%) and R-CVP (77/85, 90.6%). The number of disease relapses during rituximab maintenance did not differ significantly between the groups (p = 0.798). Therefore, the comparison of progression-free survival (PFS) showed no significant difference: the 3-year PFS rates for R-CVP and R-CHOP were 77% and 85%, respectively (p = 0.567). Although five of 56 hepatitis B virus (HBV) core antibody (anti-HBc)-positive patients experienced HBV reactivation, all cases of HBV reactivation were identified during regular monitoring for HBV DNA in blood, and were successfully managed with antiviral treatment. CONCLUSIONS: The survival outcomes of FL patients on rituximab maintenance after responding to R-CVP or R-CHOP were similar. Rituximab-containing immunochemotherapy followed by rituximab maintenance can be safely used for anti-HBc-positive patients if HBV DNA titer in blood can be regularly monitored. The Korean Association of Internal Medicine 2020-01 2019-04-04 /pmc/articles/PMC6960034/ /pubmed/30935195 http://dx.doi.org/10.3904/kjim.2018.196 Text en Copyright © 2020 The Korean Association of Internal Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kim, Hee Kyung Kang, Wonseok Sinn, Dong Hyun Lee, Joon Hyeok Kim, Won Seog Kim, Seok Jin Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
title | Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
title_full | Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
title_fullStr | Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
title_full_unstemmed | Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
title_short | Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
title_sort | real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960034/ https://www.ncbi.nlm.nih.gov/pubmed/30935195 http://dx.doi.org/10.3904/kjim.2018.196 |
work_keys_str_mv | AT kimheekyung realworlddataonfollicularlymphomapatientstreatedbyrituximabcontainingimmunochemotherapyandrituximabmaintenance AT kangwonseok realworlddataonfollicularlymphomapatientstreatedbyrituximabcontainingimmunochemotherapyandrituximabmaintenance AT sinndonghyun realworlddataonfollicularlymphomapatientstreatedbyrituximabcontainingimmunochemotherapyandrituximabmaintenance AT leejoonhyeok realworlddataonfollicularlymphomapatientstreatedbyrituximabcontainingimmunochemotherapyandrituximabmaintenance AT kimwonseog realworlddataonfollicularlymphomapatientstreatedbyrituximabcontainingimmunochemotherapyandrituximabmaintenance AT kimseokjin realworlddataonfollicularlymphomapatientstreatedbyrituximabcontainingimmunochemotherapyandrituximabmaintenance |